Panacea Biotec has introduced indigenously high quality oncology product, Cabapan (cabazitaxel injection), for treatment of metastatic castration resistant prostate cancer (mCRPC). Prostrate is the second leading site of cancer among males with rising mortality rate in India. With ever changing lifestyles, increased awareness, better diagnostic techniques and increased accessibility to medical treatment, more cases of Ca prostate are being diagnosed.
Cabapan has been developed by Panacea Biotec's global research and development center (GRAND), Mumbai and manufactured at production facility complying with global current good manufacturing practices (cGMP) at Baddi, Himachal Pradesh.
"The launch of Cabapan reflects the hard work of Panacea Biotec's scientists who worked tenaciously for the development of this drug," said Dr Rajesh Jain, joint managing director, Panacea Biotec Ltd.
